{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 4-<nowiki>[[</nowiki>(1''R'')-2-[5-(2-Fluoro-3-methoxyphenyl)-3-<nowiki>[[</nowiki>2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid
| image = Elagolix.svg
| width = 250px

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 2.4–6.3 hours<ref name="EzzatiCarr2015">{{cite journal|last1=Ezzati|first1=Mohammad|last2=Carr|first2=Bruce R|title=Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain|journal=Women's Health|volume=11|issue=1|year=2015|pages=19–28|issn=1745-5057|doi=10.2217/whe.14.68}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 834153-87-6
| CAS_supplemental = <br />{{CAS|832720-36-2}} ([[sodium]])
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 11250647
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 9425680
| KEGG = D09335
| UNII = 5B2546MB5Z

<!--Chemical data-->
| C=32 | H=30 | F=5 | N=3 | O=5
| molecular_weight = 631.589716 g/mol
| SMILES = CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F
| StdInChI = 1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1
| StdInChIKey = HEAUOKZIVMZVQL-VWLOTQADSA-N
| synonyms = Elagolix sodium, NBI-56418, ABT-620
}}

'''Elagolix''' ({{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}) (former developmental code names '''NBI-56418''', '''ABT-620''') is a highly potent, selective, [[oral administration|oral]]ly-active, short-duration, [[non-peptide]] [[gonadotropin-releasing hormone receptor antagonist|antagonist]] of the [[gonadotropin-releasing hormone receptor]] (GnRHR) ([[Dissociation constant|K<sub>D</sub>]] = 54&nbsp;[[picomolar|pM]]) which is under development for clinical use by [[Neurocrine Biosciences]] and [[AbbVie]].<ref name="pmid19006286">{{cite journal | vauthors = Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS | title = Discovery of sodium R-(+)-4-<nowiki/>{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor | journal = J. Med. Chem. | volume = 51 | issue = 23 | pages = 7478–85 | year = 2008 | pmid = 19006286 | doi = 10.1021/jm8006454 | url = }}</ref><ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1411|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=1411–}}</ref> As of 2017, it is in pre-registration for the treatment of [[endometriosis]] and [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for the treatment of [[uterine leiomyoma]].<ref name="EzzatiCarr2015" /><ref name="AdisInsight">AdisInsight: [http://adisinsight.springer.com/drugs/800020238 Elagolix].</ref> The drug was also under investigation for the treatment of [[prostate cancer]] and [[benign prostatic hyperplasia]], but development for these indications was ultimately not pursued.<ref name="AdisInsight" /> Elagolix is the first of a new class of GnRH inhibitors that have been denoted as ''second-generation'', due to their non-peptide nature and oral [[bioavailability]].<ref name="EzzatiCarr2015" />

Because of the relatively short [[elimination half-life]] of elagolix, the actions of [[gonadotropin-releasing hormone]] (GnRH) are not fully blocked throughout the day.<ref name="EzzatiCarr2015" /><ref name="pmid19033369">{{cite journal | vauthors = Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SS, Bozigian HP | title = Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix | journal = J. Clin. Endocrinol. Metab. | volume = 94 | issue = 2 | pages = 545–51 | year = 2009 | pmid = 19033369 | pmc = 2646513 | doi = 10.1210/jc.2008-1695 | url = }}</ref> For this reason, [[gonadotropin]] and [[sex hormone]] levels are only partially suppressed, and the degree of suppression can be dose-dependently adjusted as desired.<ref name="EzzatiCarr2015" /><ref name="pmid19033369" /> Moreover, if elagolix is discontinued, its effects are rapidly reversible.<ref name="EzzatiCarr2015" /><ref name="pmid19033369" /> Due to the suppression of [[estrogen]] levels by elagolix being incomplete, effects on [[bone mineral density]] are minimal, which is in contrast to first-generation [[GnRH analogue|GnRH inhibitor]]s.<ref name="pmid23885105">{{cite journal | vauthors = Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K | title = Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study | journal = Reprod Sci | volume = 21 | issue = 3 | pages = 363–71 | year = 2014 | pmid = 23885105 | doi = 10.1177/1933719113497292 | url = }}</ref><ref name="pmid25249568">{{cite journal | vauthors = Carr B, Dmowski WP, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K | title = Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density | journal = Reprod Sci | volume = 21 | issue = 11 | pages = 1341–51 | year = 2014 | pmid = 25249568 | doi = 10.1177/1933719114549848 | pmc=4212335}}</ref> Moreover, the incidence and severity of [[menopausal]] [[side effect]]s such as [[hot flash]]es are also reduced relative to first-generation GnRH inhibitors.<ref name="EzzatiCarr2015" /><ref name="pmid19033369" />

==See also==
* [[List of investigational hormonal agents#GnRH/gonadotropins|List of investigational hormonal agents § GnRH/gonadotropins]]
* [[Relugolix]]
* [[Sufugolix]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800020238 Elagolix - AdisInsight]
* [http://www.neurocrine.com/pipeline/elagolix-gnrh-antagonist/ Elagolix – GnRH Antagonist - Neurocrine Biosciences]
* [http://www.abbvie.com/research-innovation/pipeline.html Pipeline - AbbVie]

{{Gonadotropins and GnRH}}
{{Signaling peptide/protein receptor modulators}}

[[Category:Amines]]
[[Category:GnRH antagonists]]
[[Category:Trifluoromethyl compounds]]
[[Category:Pyrimidines]]
[[Category:Fluoroarenes]]


{{genito-urinary-drug-stub}}